The CALYPSO study offers valuable insights into the effectiveness of durvalumab (PD-L1 inhibitor) plus savolitinib (MET inhibitor) (D+S) in MET-driven advanced papillary renal cancer (aPRC). At 41 months follow-up, MET-driven patients achieved a 59% response rate and a median overall survival (OS) of 27.4 months, reinforcing the rationale for the ongoing SAMETA Phase III trial.
Moreover, ctDNA analysis has emerged as a promising prognostic tool, with baseline ctDNA positivity linked to shorter OS (7.3 vs. 36.4 months; p=0.02). A reduction in Variant Allele Frequency (VAF) correlated with treatment response, highlighting ctDNA clearance as a potential marker for improved outcomes (p=0.04).
A huge thank you to the experts behind this study for their dedication to advancing renal cancer research and improving patient outcomes.
Read more: https://lnkd.in/e7BQWbrv
